InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
1.670
+0.060 (3.73%)
Apr 28, 2026, 4:00 PM EDT - Market closed
InflaRx Employees
InflaRx had 65 employees as of December 31, 2025. The number of employees decreased by 9 or -12.16% compared to the previous year.
Employees
65
Change (1Y)
-9
Growth (1Y)
-12.16%
Revenue / Employee
$530
Profits / Employee
-$824,302
Market Cap
120.73M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Innate Pharma | 174 |
| Verrica Pharmaceuticals | 76 |
| Vivani Medical | 42 |
| Biomea Fusion | 41 |
| Aardvark Therapeutics | 40 |
| Equillium | 35 |
| Cardiff Oncology | 31 |
| Genelux | 26 |
IFRX News
- 16 hours ago - InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 19 days ago - InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor - GlobeNewsWire
- 4 weeks ago - InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium - GlobeNewsWire
- 4 weeks ago - InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting - GlobeNewsWire
- 5 weeks ago - InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones - GlobeNewsWire
- 5 weeks ago - InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting - GlobeNewsWire
- 6 weeks ago - InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - GlobeNewsWire
- 6 weeks ago - InflaRx to Report Full Year 2025 Results on March 19, 2026 - GlobeNewsWire